Chinese Medicine Formula Huashibaidu Granule Early Treatment for Mild COVID-19 Patients: An Unblinded, Cluster-Randomized Clinical Trial

Chinese Medicine Formula Huashibaidu Granule Early Treatment for Mild COVID-19 Patients: An Unblinded, Cluster-Randomized Clinical Trial

Background: Previous research suggested that Chinese Medicine (CM) Formula Huashibaidu granule might shorten the disease course in coronavirus disease 2019 (COVID-19) patients. This research aimed to investigate the early treatment effect of Huashibaidu granule in well-managed patients with mild COV...

Full description

Bibliographic Details
Main Authors: Chen Zhao, Li Li, Wei Yang, Wenliang Lv, Jian Wang, Jing Guo, Yu Dong, Nannan Shi, Cheng Lu, Zhiqiang Li, Zhan Shi, Renbo Chen, Ruili Huo, Qianzi Che, Yaxin Tian, Xinghua Xiang, Junhui Zhou, Yongjun Bian, Suping Chen, Yang Chen, Yingying Chen, Xiaodong Cong, Guoju Dong, Lijie Hu, Jianxin Jiang, Luxing Leng, Bin Li, Dongxu Li, Hao Li, Jing Li, Wensheng Qi, Qing Miao, Huaxin Shi, Jiaheng Shi, Bing Wang, Gang Wang, Wei Wang, Yongyue Xian, Xiaolei Xie, Chunyan Xu, Ming Xu, Bei Yan, Jinliang Yang, Li Zhang, Zhenqi Zhou, Haoning Zhu, Yibai Xiong, Bin Liu, Luqi Huang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Medicine
Subjects:
COVID-19
Chinese medicine
early treatment
Fangcang Hospital
randomized clinical trial
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2021.696976/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2021.696976/full

Similar Items